C. Reich

First name
C.
Last name
Reich
Li, X., Burn, E., Duarte-Salles, T., Yin, C., Reich, C., Delmestri, A., et al. (2022). Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. Bmj, 379, e071594. http://doi.org/10.1136/bmj-2022-071594
Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., et al. (2022). Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf, 31, 495-510. http://doi.org/10.1002/pds.5419
Matcho, A., Ryan, P., Fife, D., & Reich, C. (2014). Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. http://doi.org/10.1007/s40264-014-0214-3
Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., et al. (2020). Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keaa771
Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., et al. (2020). Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. http://doi.org/10.1016/s2665-9913(20)30276-9